Microfluidic Devices for Rapid Antimicrobial Susceptibility Testing

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

Microfluidic antimicrobial susceptibility testing (AST) devices miniaturize and automate the process of exposing bacteria to antibiotics, potentially reducing turnaround time from days to hours.
These devices work by trapping bacteria in small channels or chambers, applying controlled antibiotic gradients, and using optical or electrical sensors to detect growth changes.
The main limitation is that microfluidic AST is still largely in research and validation stages, with regulatory approval and standardization needed before routine clinical adoption.

At a Glance

Feature	Conventional AST	Microfluidic AST
Typical turnaround time	16-24 hours for standard broth dilution or disk diffusion	2-8 hours in research prototypes
Sample volume required	1-10 mL of culture	1-100 microliters
Automation potential	Moderate, requires manual steps	High, integrated sample handling and detection
Standardization status	Established CLSI standards	No universal standards yet
Clinical validation	Decades of accumulated evidence	Limited clinical validation studies
Cost per test	Low to moderate	Higher initial equipment cost

Understanding Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing determines whether a bacterial isolate is susceptible, intermediate, or resistant to specific antibiotics. This information guides treatment decisions for patients with bacterial infections. The World Health Organization identifies antimicrobial resistance as a global public health concern, and accurate susceptibility testing is essential for effective stewardship of existing antibiotics.

Conventional AST methods include broth dilution, agar dilution, disk diffusion, and gradient diffusion. These methods are standardized by organizations such as the Clinical and Laboratory Standards Institute, which publishes protocols and interpretive criteria for clinical laboratories. The standard methods require overnight incubation, typically 16 to 24 hours, because they rely on visible bacterial growth to determine the minimum inhibitory concentration (MIC).

The MIC is the lowest concentration of an antibiotic that prevents visible growth of a microorganism. This value guides clinicians in selecting the appropriate antibiotic and dosage for a patient. The delay between sample collection and susceptibility results can be clinically significant, especially for patients with severe infections such as sepsis.

Microfluidic devices address this delay by miniaturizing the AST process. These devices manipulate small volumes of fluids through channels measured in micrometers. They can create controlled environments for bacterial growth, expose bacteria to antibiotic gradients, and detect growth changes in real time. The goal is to provide clinically actionable susceptibility information within a few hours instead of a full day.

Core Principles of Microfluidic AST Devices

Microfluidic devices operate on the principle of precisely controlling small volumes of liquid in microscale channels. The behavior of fluids at this scale differs from macroscale systems, allowing for rapid mixing, reduced reagent consumption, and the ability to create controlled chemical environments.

Physical Design and Fabrication

Microfluidic devices are typically fabricated from materials such as polydimethylsiloxane, glass, or thermoplastics. Polydimethylsiloxane is common in research settings because it is transparent, gas permeable, and can be molded with high precision. Glass devices offer better chemical compatibility and optical clarity. Thermoplastics such as cyclic olefin copolymer are used when manufacturing at scale is intended.

The fabrication process involves photolithography to create a master mold, followed by casting or embossing to produce the final device. The channels are typically 10 to 100 micrometers in width and depth. The small dimensions reduce the volume of reagents and sample required, which is a practical advantage when clinical samples are limited.

The device design includes inlet ports for introducing the bacterial sample and antibiotic solutions, channels for fluid transport, and chambers where the bacteria are cultured. Some designs incorporate valves and pumps to control the flow of fluids. Others use capillary action or surface tension to move fluids without external pumps.

Bacterial Culture in Microchannels

Bacteria grow in microchannels under conditions that differ from conventional culture. The high surface area to volume ratio in microchannels can affect nutrient availability and waste removal. The small volume also means that the number of bacteria in the device is much lower than in a conventional culture, which can affect the sensitivity of detection.

The growth of bacteria in microchannels is monitored by measuring optical density, fluorescence, or electrical impedance. Optical density measurements track the increase in turbidity as bacteria multiply. Fluorescence-based detection uses fluorescent dyes that bind to DNA or metabolic activity indicators. Electrical impedance measures the change in electrical properties as bacteria grow and alter the medium.

The choice of detection method depends on the device design and the sensitivity required. Optical methods are simple and non-destructive but may require a minimum number of bacteria to produce a detectable signal. Electrical methods can detect smaller numbers of bacteria but require more complex device fabrication.

Antibiotic Gradient Generation

A key feature of microfluidic AST devices is the ability to create controlled antibiotic concentration gradients. This allows the device to expose bacteria to a range of antibiotic concentrations simultaneously, mimicking the concentration series used in conventional broth dilution.

Gradient Generators

Microfluidic gradient generators use a network of channels that mix fluids in a controlled manner. The most common design is the Christmas tree or tree-like network, where two input streams, one with antibiotic and one without, are repeatedly split and mixed to create a series of output streams with different concentrations. This design produces a linear or logarithmic gradient across the device.

The gradient is stable over time because the flow is continuous. This allows the bacteria to be exposed to a constant antibiotic concentration for the duration of the experiment. The gradient can be adjusted by changing the flow rates of the input streams or by modifying the channel geometry.

Static vs. Dynamic Conditions

Microfluidic devices can operate under static or dynamic conditions. In static devices, the bacteria and antibiotic are introduced into the chamber and the flow is stopped. The bacteria are exposed to a fixed antibiotic concentration, similar to conventional broth dilution. In dynamic devices, the flow is continuous, which can remove waste products and supply fresh nutrients.

Dynamic conditions can affect the bacterial response to antibiotics. Continuous flow can wash away signaling molecules that bacteria use to communicate, which may affect the expression of resistance genes. The flow can also create shear forces that affect bacterial physiology. These factors must be considered when interpreting results from microfluidic devices.

Detection Methods for Bacterial Growth

The detection method determines the sensitivity and speed of a microfluidic AST device. The choice of detection method affects the minimum number of bacteria that can be detected and the time required to obtain a result.

Optical Detection

Optical detection is the most common method in microfluidic AST. The device is placed on a microscope or an optical reader that measures the intensity of light transmitted through or scattered by the bacterial culture. As bacteria multiply, the optical density increases, and the change can be tracked over time.

The main advantage of optical detection is its simplicity and compatibility with transparent materials. The main limitation is the sensitivity, which requires a minimum number of bacteria to produce a detectable signal. This can extend the time to result for slow-growing bacteria or for samples with a low initial bacterial load.

Fluorescence Detection

Fluorescence detection uses fluorescent dyes or reporter molecules to detect bacterial growth. The dyes can bind to DNA, such as SYTO 9 or propidium iodide, or can be metabolic indicators that change fluorescence in response to bacterial activity. The fluorescence signal is proportional to the number of bacteria or to the metabolic activity of the bacteria.

Fluorescence detection is more sensitive than optical density, allowing detection of smaller numbers of bacteria. The tradeoff is the need for a fluorescence microscope or reader, which adds to the cost and complexity of the system. Some dyes can also affect bacterial growth, so the dye concentration must be optimized to avoid interfering with the AST result.

Electrical Detection

Electrical detection methods measure the change in electrical properties of the medium as bacteria grow. Bacteria alter the conductivity and impedance of the medium as they multiply and produce metabolic products. The impedance can be measured using electrodes integrated into the microfluidic device.

Electrical detection is label-free, meaning it does not require the addition of dyes or other reagents. This can simplify the workflow and reduce the cost per test. The sensitivity of electrical detection depends on the electrode design and the frequency of the measurement. The method is also compatible with real-time monitoring, allowing the growth curve to be tracked continuously.

Other Detection Methods

Other detection methods include electrochemical detection, which measures the production of metabolic products such as hydrogen ions or oxygen consumption, and mass spectrometry, which can identify the bacteria and detect resistance markers. These methods are less common in microfluidic AST but are being explored for specific applications.

The choice of detection method is a tradeoff between sensitivity, speed, cost, and complexity. For clinical applications, the method must be robust and reproducible, and the results must be comparable to conventional AST methods.

Comparison with Conventional AST Methods

The primary goal of microfluidic AST is to provide results that are comparable to conventional methods but with a shorter turnaround time. The comparison is made against the reference methods standardized by the CLSI.

Turnaround Time

Conventional AST methods require 16 to 24 hours of incubation. This is because the methods rely on visible bacterial growth to determine the MIC. The incubation time is a function of the bacterial growth rate and the sensitivity of the detection method.

Microfluidic devices can reduce the turnaround time by detecting bacterial growth earlier. The detection of growth in microchannels can be more sensitive than the detection of turbidity in a test tube, allowing the MIC to be determined at an earlier time point. Some research devices report results in 2 to 8 hours, depending on the bacterial species and the detection method.

The reduction in turnaround time is clinically significant. For a patient with sepsis, a 12-hour reduction in the time to susceptibility results can allow the clinician to switch from broad-spectrum antibiotics to a targeted antibiotic earlier. This can improve patient outcomes and reduce the selection pressure for antibiotic resistance.

Accuracy and Reproducibility

The accuracy of microfluidic AST must be validated against the reference methods. The MIC determined by a microfluidic device should be within the acceptable range of the reference method, typically within one doubling dilution. The reproducibility of the device must also be established, meaning the same result is obtained when the test is repeated.

The validation of microfluidic devices is complicated by the lack of standardized protocols. The CLSI has not yet published standards for microfluidic AST. Each device must be validated against the reference method using a panel of well-characterized bacterial strains, including strains with known resistance mechanisms.

The American Type Culture Collection provides authenticated bacterial strains that can be used for validation. These strains have documented susceptibility profiles and can be used to assess the accuracy of a microfluidic device. The use of authenticated strains is essential for the validation of any new AST method.

Cost and Throughput

The cost of microfluidic AST devices is a consideration for clinical laboratories. The cost includes the device itself, the reagents, the detection equipment, and the labor. The cost per test is currently higher than conventional AST, but the cost may decrease with scale and automation.

The throughput of microfluidic devices is the number of tests that can be performed in a given time. Some devices are designed for single-sample testing, while others can process multiple samples in parallel. The throughput is determined by the number of channels or chambers in the device and the time required for each test.

The throughput of microfluidic devices is generally lower than automated conventional AST systems, which can process hundreds of samples per day. However, the faster turnaround time of microfluidic devices may offset the lower throughput for urgent samples.

Practical Workflow for Evaluating Microfluidic AST

For a laboratory professional considering the adoption of microfluidic AST, the evaluation process involves several steps. The process is designed to assess the accuracy, reproducibility, and practicality of the device in the laboratory setting.

Step 1: Define the Clinical Need

The first step is to define the clinical need that the microfluidic device is intended to address. This could be the need for faster results for patients with sepsis, the need for susceptibility testing for slow-growing bacteria, or the need for a point-of-care test. The clinical need determines the performance requirements for the device.

The laboratory should identify the bacterial species that are most important for the intended use. The device must be validated for these species, as the growth characteristics and resistance mechanisms vary between species.

Step 2: Select the Device

The selection of a microfluidic device involves a review of the available devices and their specifications. The specifications include the detection method, the turnaround time, the sample volume, and the cost. The device should be compatible with the laboratory's existing equipment and workflow.

The laboratory should also consider the level of automation of the device. A device that requires significant manual handling may not be practical for a busy clinical laboratory. The device should be easy to use and require minimal training.

Step 3: Validate the Device

The validation of the device is the most critical step. The device must be validated against the reference methods using a panel of well-characterized bacterial strains. The panel should include strains with known susceptibility, intermediate resistance, and resistance to the antibiotics of interest.

The validation should assess the accuracy of the MIC determination, the reproducibility of the results, and the time to result. The validation should also assess the performance of the device with clinical samples, beyond with laboratory strains.

The validation data should be reviewed by the laboratory director and the clinical staff. The device should not be used for clinical decision-making until the validation is complete and the results are acceptable.

Step 4: Integrate into the Workflow

The integration of the device into the laboratory workflow involves the development of standard operating procedures, the training of staff, and the establishment of quality control procedures. The device should be integrated into the laboratory information system so that the results are recorded and reported.

The laboratory should also establish a process for monitoring the performance of the device over time. This includes the use of quality control strains and the monitoring of the turnaround time.

Step 5: Monitor and Escalate

The performance of the device should be monitored continuously. The laboratory should track the turnaround time, the accuracy of the results, and the rate of errors. If the device is not performing as expected, the laboratory should investigate the cause and take corrective action.

The laboratory should have a process for escalating issues to the manufacturer or to the laboratory director. If the device is not producing reliable results, the laboratory should revert to the conventional AST method until the issue is resolved.

Records and Measurements

The use of microfluidic AST devices requires the maintenance of records and measurements to ensure the quality of the results. The records should be sufficient to allow the results to be traced back to the sample and the device.

Required Records

The records should include the identification of the sample, the date and time of the test, the device used, the lot number of the device and the reagents, and the results of the test. The records should also include the quality control results for the device and the reagents.

The records should be maintained in a format that is accessible and secure. The records should be retained for a period that is consistent with the laboratory's policies and the requirements of the accreditation bodies.

Quality Control Measurements

The quality control measurements should include the use of reference strains with known susceptibility. The reference strains should be tested on a regular basis to ensure that the device is performing correctly. The results of the quality control should be recorded and reviewed.

The quality control should also include the monitoring of the device's performance over time. This includes the tracking of the turnaround time and the rate of errors. The quality control data should be used to identify trends that may indicate a problem with the device.

Measurement of Turnaround Time

The turnaround time is the time from the receipt of the sample to the time of the result. The turnaround time should be measured for each test and recorded. The turnaround time should be compared to the target turnaround time for the laboratory.

The turnaround time should be monitored over time to identify any changes in the performance of the device. An increase in the turnaround time may indicate a problem with the device or the workflow.

Common Failure Patterns

The use of microfluidic AST devices can be associated with several common failure patterns. The failure patterns can be related to the device, the sample, or the workflow.

Device-Related Failures

Device-related failures include clogging of the channels, leakage of the device, and failure of the detection system. Clogging can occur if the sample contains particles or if the bacteria form aggregates. Leakage can occur if the device is not sealed properly or if the pressure is too high.

The detection system can fail if the optical path is blocked or if the fluorescence is quenched. The failure of the detection system can result in the loss of data or the generation of inaccurate results.

Sample-Related Failures

Sample-related failures include the presence of contaminants in the sample, the low number of bacteria in the sample, and the presence of inhibitors in the sample. The presence of contaminants can affect the growth of the bacteria and the interpretation of the results.

The low number of bacteria in the sample can result in a failure to detect growth, which can lead to a false susceptible result. The presence of inhibitors can affect the growth of the bacteria and the results of the test.

Reagent-Related Failures

Reagent-related failures include the degradation of the antibiotics, the contamination of the reagents, and the incorrect concentration of the reagents. The degradation of the antibiotics can result in a false susceptible result. The contamination of the reagents can result in the growth of the contaminating bacteria, which can affect the results.

The incorrect concentration of the reagents can result in an incorrect MIC. The concentration of the antibiotics must be verified before the test is performed.

Safety and Biosafety Considerations

The use of microfluidic AST devices involves the handling of bacterial cultures and clinical samples. The laboratory must follow the biosafety guidelines to protect the laboratory staff and the environment.

Risk Assessment

The risk assessment is the first step in the biosafety process. The risk assessment should consider the pathogenicity of the bacteria being handled, the route of transmission, and the concentration of the bacteria. The risk assessment should be based on the Biosafety in Microbiological and Biomedical Laboratories guidelines.

The risk assessment should be performed by the laboratory director or the biosafety officer. The risk assessment should be documented and reviewed periodically.

Containment

The containment of the bacteria is essential to prevent the release of the bacteria into the environment. The microfluidic devices should be handled in a biosafety cabinet if the bacteria are potentially infectious. The devices should be disposed of in a manner that is consistent with the laboratory's policies.

The containment should be appropriate for the risk group of the bacteria. The bacteria should be handled at the appropriate biosafety level, which is determined by the risk assessment.

Decontamination

The decontamination of the devices and the waste is essential to prevent the spread of the bacteria. The devices should be decontaminated after use, and the waste should be disposed of in a manner that is consistent with the laboratory's policies.

The decontamination methods should be validated to ensure that they are effective. The decontamination should be performed by trained staff.

Professional Escalation Criteria

The laboratory professional should escalate issues to the appropriate person when the device is not performing as expected or when the results are questionable.

When to Escalate

The laboratory professional should escalate the issue to the laboratory director or the supervisor when the device is not producing reliable results. The escalation should occur when the quality control fails, when the results are inconsistent, or when the device is not functioning properly.

The laboratory professional should also escalate the issue when the results are unexpected or when the results are not consistent with the clinical picture. The escalation should occur when the results are not consistent with the results of the conventional methods.

How to Escalate

The escalation should be documented and communicated to the appropriate person. The escalation should include the details of the issue, the results of the test, and the actions that have been taken. The escalation should be done in a timely manner.

The laboratory director should review the issue and determine the appropriate action. The action may include the investigation of the issue, the repetition of the test, or the use of the conventional methods.

Decision Framework for Selecting Between Microfluidic and Conventional AST

Clinical microbiologists face a practical decision when a microfluidic AST device becomes available for evaluation. The decision is not simply whether the technology works, but whether it fits the laboratory's workflow, patient population, and quality requirements. A structured decision framework helps laboratories avoid the common error of adopting a device based on speed alone without considering accuracy, cost, and operational fit.

Step 1: Define the Target Patient Population and Clinical Use Case

The first decision point is identifying which patients will benefit most from faster susceptibility results. The World Health Organization emphasizes that antimicrobial resistance threatens the effectiveness of existing treatments, and timely susceptibility data supports stewardship efforts. Laboratories should specify the clinical scenarios where a 12 to 18 hour reduction in turnaround time changes patient management.

The clearest use case is sepsis or bloodstream infections where the patient is receiving broad-spectrum empiric therapy. For these patients, earlier targeted therapy can reduce the duration of unnecessary antibiotic exposure. A second use case is infections caused by slow-growing organisms, where conventional AST may require 48 to 72 hours. A third use case is outpatient settings where a same-day result avoids a second patient visit.

The laboratory should document the expected number of samples per day for each use case. This number determines whether the device throughput is sufficient. A device that processes one sample per hour may be adequate for a laboratory receiving five urgent samples per day but inadequate for a laboratory receiving fifty.

Step 2: Assess the Bacterial Panel and Antibiotic Panel Requirements

The device must be validated for the bacterial species and antibiotics that the laboratory routinely tests. The Clinical and Laboratory Standards Institute publishes standards for conventional AST methods, and these standards define the interpretive criteria for susceptibility categories. The microfluidic device must produce results that are comparable to these standards.

The laboratory should create a list of the top ten bacterial species isolated from the target patient population. For each species, the laboratory should list the antibiotics that are routinely tested and reported. The device must be able to test these antibiotics at the concentrations that are clinically relevant.

The device should also be assessed for its ability to detect specific resistance mechanisms. For example, if the laboratory serves a population with a high prevalence of methicillin-resistant Staphylococcus aureus, the device must reliably detect oxacillin resistance. If the laboratory serves a population with a high prevalence of extended-spectrum beta-lactamase producing Enterobacterales, the device must reliably detect resistance to third-generation cephalosporins.

Step 3: Assess the Device Against the Reference Method

The device must be compared to the reference method that the laboratory currently uses. The comparison should use a panel of well-characterized bacterial strains, including strains with known susceptibility, intermediate resistance, and resistance. The American Type Culture Collection provides authenticated strains with documented susceptibility profiles that are suitable for this purpose.

The comparison should assess the categorical agreement, which is the percentage of results that fall into the same susceptibility category, susceptible, intermediate, or resistant, as the reference method. The comparison should also assess the essential agreement, which is the percentage of results that are within one doubling dilution of the reference MIC.

The laboratory should establish acceptable thresholds for these agreement measures before starting the evaluation. A common threshold is 90 percent categorical agreement and 90 percent essential agreement. The laboratory should also assess the rate of very major errors, where the device reports susceptible but the reference method reports resistant, and major errors, where the device reports resistant but the reference method reports susceptible. The acceptable rates for these errors should be defined in advance.

Step 4: Assess the Operational Fit

The operational fit includes the physical space, the staffing, and the existing laboratory information system. The device should fit into the laboratory's existing workflow without requiring a major redesign of the laboratory space. The device should be compatible with the laboratory's existing biosafety practices, which are based on the Biosafety in Microbiological and Biomedical Laboratories guidelines.

The staffing assessment should consider the time required to operate the device. A device that requires a dedicated operator for each run may not be practical for a laboratory with limited staff. The device should be operable by the existing laboratory staff after a reasonable training period.

The device should also be compatible with the laboratory information system. The results should be transferable to the laboratory information system without manual transcription, which can introduce errors. The device should produce a report that is readable by the clinical staff and that includes the necessary interpretive comments.

Step 5: Calculate the Cost per Reportable Result

The cost per reportable result is the total cost of the device, the reagents, the consumables, the labor, and the quality control, divided by the number of reportable results. This calculation is different from the cost per test, because some tests may fail and need to be repeated.

The laboratory should estimate the cost of the device over its expected lifespan, including the maintenance and the service contract. The cost of the reagents and consumables should be estimated based on the expected number of tests per year. The labor cost should be estimated based on the time required for each test and the hourly rate of the laboratory staff.

The cost per reportable result should be compared to the cost of the conventional AST method. The comparison should also consider the cost of the clinical consequences of a delayed result. A faster result may reduce the length of stay in the hospital, which can offset the higher cost of the device.

Step 6: Establish the Quality Control and Proficiency Testing Plan

The quality control plan should include the use of reference strains with known susceptibility. The reference strains should be tested on a regular basis, typically with each batch of tests or at least once per day. The results of the quality control should be recorded and reviewed.

The proficiency testing plan should include the participation in an external proficiency testing program, if one is available for microfluidic AST. The proficiency testing program provides samples with known results, and the laboratory's results are compared to the expected results. The proficiency testing program is a requirement for many laboratory accreditation bodies.

The quality control and proficiency testing results should be reviewed by the laboratory director on a regular basis. The review should identify any trends that may indicate a problem with the device or the reagents.

Step 7: Define the Escalation and the Reversion Criteria

The laboratory should define the criteria for escalating an issue to the manufacturer or the laboratory director. The escalation criteria should include the failure of the quality control, the failure of the proficiency testing, and the unexpected results that are not consistent with the clinical picture.

The laboratory should also define the criteria for reverting to the conventional AST method. The revert criteria should include the failure of the device to produce reliable results, the failure of the device to meet the performance thresholds, and the failure of the device to be repaired in a timely manner.

The revert procedure should be documented and the staff should be trained on the procedure. The revert procedure should be activated when the device is not performing as expected, and the laboratory should not use the device for clinical decision-making until the issue is resolved.

Records and Measurements for the Decision Framework

The decision framework requires the maintenance of records that document the evaluation process and the ongoing performance of the device. The records should be sufficient to allow the laboratory to demonstrate that the device is performing as expected and that the decision to adopt the device was based on the evidence.

Evaluation Records

The evaluation records should include the protocol for the evaluation, the results of the evaluation, and the conclusion of the evaluation. The protocol should describe the bacterial strains, the antibiotics, the reference method, and the acceptance criteria. The results should include the categorical agreement, the essential agreement, the major error rate, and the very major error rate.

The evaluation records should also include the documentation of the operational fit, including the training records, the standard operating procedures, and the quality control plan. The evaluation records should be reviewed by the laboratory director and the clinical staff.

Ongoing Performance Records

The ongoing performance records should include the quality control results, the proficiency testing results, and the turnaround time measurements. The quality control results should be recorded for each day of testing. The proficiency testing results should be recorded for each round of the proficiency testing program.

The turnaround time should be measured for each test and recorded. The turnaround time should be compared to the target turnaround time for the laboratory. The turnaround time should be monitored over time to identify any changes in the performance of the device.

The Decision Log

The decision log should document the decisions that are made about the device. The decision log should include the decision to adopt the device, the decision to continue using the device, and the decision to revert to the conventional method. The decision log should include the rationale for each decision and the evidence that supports the decision.

The decision log should be reviewed by the laboratory director on a regular basis. The decision log should be retained for a period that is consistent with the laboratory's policies and the requirements of the accreditation bodies.

Common Failure Patterns in the Decision Process

The decision process can fail in several ways. The failures can be related to the evaluation, the implementation, or the ongoing monitoring.

Evaluation Failures

The evaluation failures include the use of an inadequate panel of bacterial strains, the use of the wrong reference method, and the use of the wrong comparison criteria. The evaluation can also fail if the device is not tested with the clinical samples that are representative of the laboratory's patient population.

The evaluation can also fail if the device is not tested under the conditions that will be used in the clinical setting. For example, if the device is tested with a pure culture but the clinical sample is a mixed culture, the evaluation may not be representative.

Implementation Failures

The implementation failures include the failure to train the staff, the failure to develop the standard operating procedure, and the failure to integrate the device into the laboratory information system. The implementation can also fail if the device is not compatible with the laboratory's existing equipment.

The implementation can also fail if the device is not placed in a location that is convenient for the staff. The device should be placed in a location that is accessible and that does not interfere with the existing workflow.

Monitoring Failures

The monitoring failures include the failure to record the quality control results, the failure to review the quality control results, and the failure to act on the quality control results. The monitoring can also fail if the turnaround time is not measured or if the turnaround time is not reviewed.

The monitoring can also fail if the laboratory does not participate in the external proficiency testing program. The proficiency testing program is an important part of the quality assurance for the device.

Safety and Biosafety Context for the Decision

The decision framework should include the biosafety considerations for the device. The device should be handled in a manner that is consistent with the biosafety guidelines. The laboratory should perform a risk assessment for the device, considering the pathogenicity of the bacteria, the route of transmission, and the concentration of the bacteria.

The device should be handled in a biosafety cabinet if the bacteria are potentially infectious. The device should be disposed of in a manner that is consistent with the laboratory's policies. The decontamination of the device should be performed after the use.

The biosafety considerations should be documented in the standard operating procedure for the device. The staff should be trained in the biosafety procedures for the device.

Professional Escalation Criteria for the Decision

The laboratory professional should escalate the issues to the appropriate person when the device is not performing as expected or when the results are questionable. The escalation should occur when the quality control fails, when the results are inconsistent, or when the device is not functioning properly.

The escalation should also occur when the results are unexpected or when the results are not consistent with the clinical picture. The escalation should occur when the results are not consistent with the results of the conventional methods.

Frequently Asked Questions

How does a microfluidic device determine the minimum inhibitory concentration?

The device creates a concentration gradient of the antibiotic across the microchannels. The bacteria are exposed to the gradient, and the growth of the bacteria is monitored. The MIC is the lowest concentration of the antibiotic that prevents the growth of the bacteria.

What is the typical turnaround time for a microfluidic AST device?

The turnaround time for microfluidic AST devices is typically 2 to 8 hours, depending on the device and the bacterial species. This is faster than the conventional 16 to 24 hours.

Are microfluidic AST devices approved for clinical use?

Most microfluidic AST devices are still in the research and development stage. The devices have not yet been approved by the regulatory agencies for clinical use. The approval requires the validation of the device against the reference methods.

How do microfluidic devices compare to conventional AST methods?

Microfluidic devices can provide faster results than conventional methods, but the accuracy and reproducibility must be validated. The devices are not yet standardized, and the results must be compared to the reference methods.

What are the limitations of microfluidic AST devices?

The limitations include the lack of standardization, the higher cost, and the need for validation. The devices may also be affected by the sample quality and the bacterial growth characteristics.

Can microfluidic devices be used for all bacterial species?

The devices can be used for a range of bacterial species, but the performance must be validated for each species. The growth rate and the resistance mechanisms vary between species, which can affect the results.

What is the role of the CLSI in microfluidic AST?

The CLSI publishes standards for conventional AST methods. The CLSI has not yet published standards for microfluidic AST. The standards are needed for the standardization of the devices.

How should a laboratory validate a microfluidic AST device?

The laboratory should validate the device against the reference methods using a panel of well-characterized bacterial strains. The validation should include the accuracy, the reproducibility, and the turnaround time.

Using the Evidence

Source	Best use in this topic	Important limitation
Biosafety in Microbiological and Biomedical Laboratories	official guidance	Check the linked page for current local requirements
Microbiology Resources	official guidance	Check the linked page for current local requirements
Antimicrobial Resistance	official guidance	Check the linked page for current local requirements

Related Bacteriology Guides

References and Further Reading

Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
Microbiology Resources. American Society for Microbiology.
Antimicrobial Resistance. World Health Organization.
Bacteriological Analytical Manual. U.S. Food and Drug Administration.
Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
Culture Collections. American Type Culture Collection.
NCBI Pathogen Detection. National Center for Biotechnology Information.
Microfluidic technologies for advanced antimicrobial susceptibility testing.. Biomicrofluidics, 2024.
Conventional methods and future trends in antimicrobial susceptibility testing.. Saudi journal of biological sciences, 2023.
Microfluidic Systems for Antimicrobial Susceptibility Testing.. Advances in biochemical engineering/biotechnology, 2022.
Nucleic acid amplification-based microfluidic approaches for antimicrobial susceptibility testing.. The Analyst, 2021.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.